Association of common variant rs9934336 of SLC5A2 (SGLT2) gene with SARS-CoV-2 infection and mortality
Abstract COVID-19 has its life-threatening complications more pronounced in people with underlying health conditions such as diabetes, cardiovascular disease and kidney disease. Inhibition of the sodiumglucose cotransporter 2 (SGLT2), which primarily increases urinary glucose excretion, is shown to...
Main Authors: | Anamika Das, Gunanidhi Dhangadamajhi |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2024-01-01
|
Series: | Egyptian Journal of Medical Human Genetics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43042-024-00481-x |
Similar Items
-
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
by: Yao Hao Teo, et al.
Published: (2021-03-01) -
Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01) -
SGLT2 Inhibitors as Potential Anticancer Agents
by: Debasish Basak, et al.
Published: (2023-06-01) -
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
by: Keming Huang, et al.
Published: (2023-04-01) -
Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
by: David Bobrowski, et al.
Published: (2021-11-01)